AU2020364246A1 - Analgesic and anesthetic peptides and other agents - Google Patents

Analgesic and anesthetic peptides and other agents Download PDF

Info

Publication number
AU2020364246A1
AU2020364246A1 AU2020364246A AU2020364246A AU2020364246A1 AU 2020364246 A1 AU2020364246 A1 AU 2020364246A1 AU 2020364246 A AU2020364246 A AU 2020364246A AU 2020364246 A AU2020364246 A AU 2020364246A AU 2020364246 A1 AU2020364246 A1 AU 2020364246A1
Authority
AU
Australia
Prior art keywords
peptide
pain
ap2a2
injection
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020364246A
Other languages
English (en)
Inventor
Arindam Bhattacharjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU2020364246A1 publication Critical patent/AU2020364246A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020364246A 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents Abandoned AU2020364246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913512P 2019-10-10 2019-10-10
US62/913,512 2019-10-10
PCT/US2020/055289 WO2021072392A1 (en) 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents

Publications (1)

Publication Number Publication Date
AU2020364246A1 true AU2020364246A1 (en) 2022-05-12

Family

ID=75437541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020364246A Abandoned AU2020364246A1 (en) 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents

Country Status (10)

Country Link
US (1) US20240294571A1 (https=)
EP (1) EP4051690A4 (https=)
JP (1) JP2022551467A (https=)
KR (1) KR20220079651A (https=)
CN (1) CN114829372A (https=)
AU (1) AU2020364246A1 (https=)
BR (1) BR112022006862A2 (https=)
CA (1) CA3157686A1 (https=)
IL (1) IL292102A (https=)
WO (1) WO2021072392A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025029752A2 (en) * 2023-07-28 2025-02-06 Gate Science, Inc. Methods and systems for pain management and testing thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733719B2 (en) * 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
IL136076A0 (en) * 1997-11-26 2001-05-20 Zymogenetics Inc Mammalian cytokin-like polypeptide -10
KR20030069989A (ko) * 2000-09-08 2003-08-27 다이이찌 산토리 파마 가부시키가이샤 심부전 치료제
PL2211873T3 (pl) * 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
WO2012019192A2 (en) * 2010-08-06 2012-02-09 Mount Sinai School Of Medicine Cell-permeable molecules as growth factor receptor antagonists
CN111712252A (zh) * 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
CN112218650A (zh) * 2018-01-15 2021-01-12 单侧Ip私人有限公司 肽及其用途

Also Published As

Publication number Publication date
CN114829372A (zh) 2022-07-29
JP2022551467A (ja) 2022-12-09
CA3157686A1 (en) 2021-04-15
US20240294571A1 (en) 2024-09-05
KR20220079651A (ko) 2022-06-13
IL292102A (en) 2022-06-01
WO2021072392A1 (en) 2021-04-15
BR112022006862A2 (pt) 2022-07-05
EP4051690A1 (en) 2022-09-07
EP4051690A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
Bourinet et al. Silencing of the Cav3. 2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception
Walrave et al. I nhibition of astroglial connexin43 hemichannels with TAT‐G ap19 exerts anticonvulsant effects in rodents
US12077610B2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
AU2025271034A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
James et al. Pharmacotherapy of painful diabetic neuropathy: a clinical update
Jiang et al. Cardiac-specific overexpression of Claudin-5 exerts protection against myocardial ischemia and reperfusion injury
US11365413B2 (en) Inhibition of poly(A) binding protein and the treatment of pain
JP2019522989A (ja) ＴＡＴκ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
US20240294571A1 (en) Analgesic and anesthetic peptides and other agents
Faustini et al. Improved tendon repair with optimized chemically modified mRNAs: Combined delivery of Pdgf-BB and IL-1Ra using injectable nanoparticles
WO2011148200A1 (en) Treatment of pain
US20210379104A1 (en) Pharmaceutical composition comprising isolated mitochondria for preventing or treating tendinopathy
Li et al. Netrin-1 contributes to peripheral nerve injury induced neuropathic pain via regulating phosphatidylinositol 4-kinase IIa in the spinal cord dorsal horn in mice
US9993522B2 (en) Treatment of pain by inhibition of USP5 de-ubiquitinase
KR20130027016A (ko) 포유류와 인간 세포에서 ｈｉｖ 복제를 억제하는 방법
Lai et al. CtBP1 is essential for epigenetic silencing of μ-opioid receptor genes in the dorsal root ganglion in spinal nerve ligation-induced neuropathic pain
US20100292454A1 (en) Neuronal regeneration promoting agent
US20250064846A1 (en) Treatment and prevention of trigeminal neuralgia
AU2019325622C1 (en) Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
Powell II Nociceptor Endocytosis Regulates Inflammatory Pain
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
WO2024182357A1 (en) Compositions and methods for the chronic treatment of epilepsy and epileptogenesis
Thakor Development of a novel sensory neuron gene delivery platform with concomitant investigation of messenger ribonucleic acid translocation for the NaV1. 8 sodium channel during neuropathic pain
CN120919278A (zh) CRHR2拮抗剂Astressin 2B治疗神经病理性疼痛治疗药物中的应用
NZ749459A (en) TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application